A medical executive based in Wilmington, Delaware, Robert Hindes, MD, is the cofounder and chief medical officer of Trek Therapeutics. In his leadership role, Robert Hindes, MD, helps to develop the company’s clinical strategy and oversees all clinical activities involving such portfolio products as faldaprevir and TD-6450.
A protease inhibitor acquired from Boehringer Ingelheim, faldaprevir (FDV) has undergone Phase 3 clinical trials in combination with ribavirin (RBV) and Peg IFN. In a Phase 2 study involving individuals with HCV genotype 1a, FDV treatment was combined with RBV, the 5A inhibitor PPI-668, and the non-nucleoside inhibitor deleobuvir. After a 12-week treatment course, subjects exhibited a sustained viral response (SVR) of 92 percent.
The TREKtx portfolio also includes TD-6450, an NS5A inhibitor obtained from Theravance Biopharma that demonstrated best-in-class dose-dependent antiviral activity in subjects with HCV genotype 1. In October of 2015, TREKtx initiated a Phase 2a clinical trial involving faldaprevir administered in combination with TD-6450 and RBV to subjects with genotype 4 HCV.
A protease inhibitor acquired from Boehringer Ingelheim, faldaprevir (FDV) has undergone Phase 3 clinical trials in combination with ribavirin (RBV) and Peg IFN. In a Phase 2 study involving individuals with HCV genotype 1a, FDV treatment was combined with RBV, the 5A inhibitor PPI-668, and the non-nucleoside inhibitor deleobuvir. After a 12-week treatment course, subjects exhibited a sustained viral response (SVR) of 92 percent.
The TREKtx portfolio also includes TD-6450, an NS5A inhibitor obtained from Theravance Biopharma that demonstrated best-in-class dose-dependent antiviral activity in subjects with HCV genotype 1. In October of 2015, TREKtx initiated a Phase 2a clinical trial involving faldaprevir administered in combination with TD-6450 and RBV to subjects with genotype 4 HCV.